Check out our COVID-19 dedicated page for tenders related to medical equipment needs.
United Kingdom-London: Medical software development services
Prior information notice
This notice aims at reducing time limits for receipt of tenders
Section I: Contracting authority
Section II: Object
Vigilance Signal Detection and Management Technology Systems and Associated Services
The SafetyConnect programme is a technology-enabled strategic business change programme. It aims to significantly enhance the UK’s vigilance capability and revolutionise the way it shares and uses information for the greatest public health impact. The programme will achieve this by investing in increased technological capabilities that can better analyse and respond to adverse drug reactions and incidents related to medical devices and blood reported by patients, the healthcare community and manufacturers.
This is an integral part of the Agency’s overall ambition and provides a unique opportunity to transform how the Agency monitors and acts on safety insights across the full product lifecycle, through joined up safety vigilance, reporting and information.
The MHRA are seeking to procure new systems and associated services to replace its existing specialist signal detection, case management and analytics systems used in its pharmacovigilance and medial product vigilance activities.
Deliver the core capabilities of signal detection and management, integrated case management and vigilance analytics — the MHRA require solution(s) and associated services to provide a comprehensive capability to manage signal detection, vigilance caseloads, and analytics across all medicines and healthcare products. This includes migration from current systems. The MHRA is also looking to automate (where feasible) signal detection, safety updates and distribution of reporting to speed-up analytics and knowledge sharing.
The MHRA have a need for a proven machine learning and natural language processing solution to assist in the receipt and processing of specific adverse drug reactions. This solution is required to replace an interim solution to ensure that all additional case details are automatically detected from reaction text.
Section III: Legal, economic, financial and technical information
Section IV: Procedure
Section VI: Complementary information